Good news

3
Comment
Favorite

jyt20275
2021-08-23

Good news

Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion

Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics

Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":835232898,"tweetId":"835232898","gmtCreate":1629719550714,"gmtModify":1676530110055,"author":{"id":3581983450078020,"idStr":"3581983450078020","authorId":3581983450078020,"authorIdStr":"3581983450078020","name":"jyt20275","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good news</p></body></html>","htmlText":"<html><head></head><body><p>Good news</p></body></html>","text":"Good news","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/835232898","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":65,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}